(Q30327421)

18 June 2017

1 reference

title

Prostate cancer immunotherapy at the dawn of the new millennium. (English)

1 reference

18 June 2017

1 reference

1 reference

Salgaller ML

1

1 reference

18 June 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

Expert Opinion on Investigational Drugs

18 June 2017

published in

1 reference

18 June 2017

volume

9

1 reference

18 June 2017

issue

6

1 reference

18 June 2017

page(s)

1217-1229

1 reference

18 June 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Tamoxifen in advanced prostate cancer: An ECOG pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Treatment of metastatic prostate cancer. Lessons from the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Estrogen receptor expression in prostate cancer and premalignant prostatic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Immunological aspects of malignant disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Tumor Vaccine Design: Concepts, Mechanisms, and Efficacy Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Tumor immunology: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Tumor escape from immune response by variation in HLA expression and other mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Identification of human cancers deficient in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Selection of potent immunological adjuvants for vaccine construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

The human hematopoietic colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Use of cellular and cytokine adjuvants in the immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Epitope selection and development of peptide based vaccines to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Capture and processing of exogenous antigens for presentation on MHC molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

Tumour surveillance: missing peptides and MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.6.1217

A safe packaging line for gene transfer: separating viral genes on two different plasmids

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1128/JVI.62.4.1120-1124.1988

Identifiers

DOI

10.1517/13543784.9.6.1217

1 reference

18 June 2017

1 reference